BiotechTube
Azitra

Azitra

AZTR
United States
azitrainc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

AZTR · Stock Price

USD 0.24-1.73 (-87.90%)
Market Cap: $3.9M

Historical price data

Overview

Azitra is a clinical-stage biopharmaceutical company focused on developing precision dermatology treatments by engineering the skin's native microbiome. Its core strategy utilizes a proprietary platform combining a large microbial library, AI/ML screening, and genetic engineering to create live biotherapeutic products and engineered proteins. The company's lead program, ATR-12, targets the rare disease Netherton syndrome, with a pipeline extending to oncology supportive care and common dermatoses.

DermatologyRare DiseasesOncology Supportive Care

Technology Platform

A proprietary platform integrating a library of ~1,500 human skin bacterial strains, AI/ML screening, and genetic engineering technology to create engineered live biotherapeutic products and proteins for dermatological diseases.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
ATR-04Epidermal Growth FactorPhase 1/2
ATR04-484 + VehicleEGFR Inhibitor-associated RashPhase 1/2
ATR12-351Netherton SyndromePhase 1

Funding History

3
Total raised:$26M
IPO$15M
Series A$8.5M
Seed$2.5M

Opportunities

The primary near-term opportunity is clinical validation of its platform via the ATR-12 trial in Netherton syndrome, a high-unmet-need rare disease.
Long-term, the platform's modularity allows rapid generation of new candidates for multiple dermatologic conditions, creating a pipeline-in-a-product model with significant potential in rare diseases and large markets like oncology supportive care.

Risk Factors

Key risks include clinical trial failure of its lead asset, the evolving and uncertain regulatory pathway for engineered live biotherapeutics, and a precarious financial position requiring near-term capital raises in a challenging market for micro-cap biotechs.

Competitive Landscape

Azitra faces competition from systemic biologics and other investigational therapies in its target indications, but its core approach—engineering native skin commensals to deliver therapeutics locally—is a key differentiator. It occupies a specialized niche within the broader, emerging microbiome therapeutics space.

More companies in Microbiome Therapeutics →More companies in United States →